Kotak Institutional Equities says worst of price war in diagnostics behind us but stays cautious; here's why
The brokerage has a 'sell' call on Dr Lal with a target price of 1,740, implying a potential downside of over 30 percent. Meanwhile, it has a 'reduce' call on Metropolis with a target price of 1,350, indicating an over 7 percent downside.
Dr. Lal PathLabs Ltd - 539524 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2023.
Hot Stocks | Here's why you should bet on Dr Lal PathLabs, RBL Bank for short term
Dr Lal PathLabs has seen a spectacular run in this financial year, garnering over 35 percent returns for its investors, while RBL Bank has been one of the outperforming stocks in the space. Dr. Lal PathLabs Ltd - 539524 - Closure of Trading Window
Intimation for Closure of Trading Window Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meetings Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Investor Meetings Dr. Lal PathLabs Ltd - 539524 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Scrutinizer''s Report and voting Results of 29th AGM Dr. Lal PathLabs Ltd - 539524 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of 29th Annual General Meeting Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Investor Meet Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Allotment
Intimation regarding allotment of Equity Shares under ESOP Plan 2010